World Nucleoside-based Antiviral Drug Market Report: Latest Data on Sales Volume, Market Share, and Growth Rate 2026-2032
Nucleoside antiviral drugs refer to a category of antiviral medications. The global market for nucleoside antiviral drugs is estimated to reach approximately \$2.18 billion by 2025, with a projected CAGR of 5.3% from 2026 to 2032, reaching around \$3.135 billion by 2032. Nucleoside antiviral drugs are used in the treatment of conditions such as HIV, hepatitis B and C, herpes viruses, and cytomegalovirus, and they create stable demand primarily for formulations aimed at chronic diseases that require long-term administration.
Inquire About This Product
basic information
Global Market Size of Nucleoside Antiviral Drugs According to the latest research report published by Global Reports, titled "Global Market Size, Share, Company Rankings, Sales, and Demand Trend Forecast for Nucleoside Antiviral Drugs (2026-2032)," the global market size for nucleoside antiviral drugs is expected to expand from approximately 2,180 million USD in 2025 to around 2,300 million USD in 2026. It is projected to continue growing at a compound annual growth rate (CAGR) of 5.3%, reaching approximately 3,135 million USD by 2032.
Price range
Delivery Time
Applications/Examples of results
Structure of Nucleoside-based Antiviral Drugs Nucleoside-based antiviral drugs are pharmaceutical-grade active ingredients based on nucleoside analogs, nucleotide analogs, and related prodrugs. Representative products include acyclovir, valacyclovir, ganciclovir, valganciclovir, lamivudine, emtricitabine, tenofovir, entecavir, sofosbuvir, and remdesivir. Upstream of nucleoside-based antiviral drugs, nucleobases, sugar-addition intermediates, chiral intermediates, phosphorylation reagents, protecting group reagents, catalysts, solvents, and purification resins are required. Supply and Pricing of Nucleoside-based Antiviral Drugs The global effective production capacity of nucleoside-based antiviral drugs is estimated to be approximately 21,500 tons in 2025, with sales volume around 14,860 tons and an average factory shipment price of about $146.7 per kg. Mature products such as acyclovir, lamivudine, and tenofovir disoproxil fumarate are relatively low-priced, while valganciclovir, tenofovir alafenamide, sofosbuvir, and remdesivir have higher synthesis difficulty and quality control requirements, leading to increased unit prices. The industry's gross profit margin is expected to be around 28-42% in 2025.
Company information
Global Reports integrates industrial information from around the world and provides highly accurate market intelligence to support corporate decision-making. We deliver in-depth analyses based on numerical data and facts, including market size, share, industry structure, price trends, growth forecasts, rankings of major companies, and competitive trends, with clear information categorized by country, region, and application. Leveraging a rich database that has supported the business growth of over 65,000 companies and an international research network, we accompany our clients in their global expansion and continuous growth.
